Description: Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.
Home Page: www.addextherapeutics.com
ADXN Technical Analysis
Chemin des Mines, 9
Geneva,
1202
Switzerland
Phone:
41 22 884 1555
Officers
| Name | Title |
|---|---|
| Mr. Timothy Mark Dyer | Co-Founder, CEO & Director |
| Dr. Roger G. Mills M.D. | Chief Medical Officer & Director |
| Mr. Lénaic Teyssédou | Head of Fin. |
| Dr. Jean-Philippe Rocher Ph.D. | Head of Discovery - Chemistry |
| Dr. Robert Lutjens | Head of Discovery - Biology |
| Dr. Mikhail Kalinichev Ph.D. | Head of Translational Science |
| Dr. Werner Henrichi Ph.D. | Consultant |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4085 |
| Price-to-Sales TTM: | 10.2796 |
| IPO Date: | 2020-01-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 26 |